Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19
April 06 2020 - 9:25AM
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer
of rapid health information technologies, today announced that its
collaboration with Premas Biotech has successfully completed the
milestone of obtaining clones of all three coronavirus antigens,
Spike (S), Envelope (E), and Membrane (M) that they have selected
for their vaccine candidate.
The clone development process has four primary
steps including first, the design and synthesis of the genes;
second, the selection of the right host; third, the insertion of
the gene into the host; and fourth, the verification that the clone
has the right gene, and all characteristics are correct.
Prabuddha Kundu, Co-Founder and Managing
Director at Premas Biotech, commented, “We are pleased with the
successful completion of this phase in the development of our novel
vaccine candidate. We believe that our ability to clone all three
of these antigens will differentiate our vaccine candidate from
others. Specifically, the surface of a virus is what the immune
systems sees, and importantly has a multitude of proteins. We are
providing the immune system with three shots on goal, instead of
one, by including S, E, and M together. This is increasingly
important due to the likelihood of protein mutation. If a protein
mutates, a vaccine can be rendered non efficacious, a scenario
often faced with seasonal flu variations. By including three at one
time, the immune system can still recognize the other two antigens,
which we believe will enhance its efficacy and assist us in making
this vaccine candidate successful.”
Christopher Schreiber, Executive Chairman of
Akers, stated, “We believe that we are one step closer to an
effective vaccine candidate for the coronavirus pandemic. We have
now completed our first important milestone by generating these
clones. We also have initiated the second stage in protein
expression, which we hope to provide an update on later this month.
We are optimistic about the continued success of our partnership
with Premas, one that is already starting to bear fruit.”
About Premas Biotech
Premas Biotech develops novel technologies and
partners with global biopharmaceutical companies to build and
develop novel biotherapeutic & vaccine candidates. Premas' key
focus areas are infectious diseases, cancer, metabolic
disorders and inflammation. Besides D-CryptTM the difficult to
express proteins expression platform, Premas’ leading technologies
include Axtex-4D™: an ex-vivo tissueoid generation platform and
C-Qwence™: a fully human naive India based scFv antibody library.
Further information is available on the Company’s
website: www.premasbiotech.com
Contact email: contact@premasbiotech.com
About Akers Biosciences
Inc.
Akers Biosciences is pursuing the development of
a newly acquired license to a coronavirus vaccine candidate. In
addition, the company develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
health related information directly to the patient or clinician in
a timely and cost-efficient manner. Akers has previously announced
that that it had identified the hemp and minor cannabinoid
sectors as promising adjacent opportunities that could benefit from
Akers’ existing facility and its core competencies.
Forward-Looking Statements
Statements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts and
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include any risks
detailed from time to time in Akers' reports filed with the
Securities and Exchange Commission, Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although Akers believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. Akers does not have any obligation
to update these forward-looking statements other than as required
by law.
Additional information on the company and its products can be
found at www.akersbio.com.
Contact:
Investor Relations:Hayden IRBrett Mass, Managing
PartnerPhone: (646)
536-7331Email: brett@haydenir.comwww.haydenir.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2023 to Sep 2024